Form D · Other Health Care
RS BioTherapeutics Inc.
Cumberland, MD · CIK 0001932193
Offering snapshot reported Oct 9, 2024 · SEC filing
- Reported sold
- $20K Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 26, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2024 | Initial | $20,000 | No comparison | 1 | SEC filing |
| Oct 19, 2023 | Amendment | $1,105,000 | $855,000vs Aug 10, 2023 | 5 | SEC filing |
| Aug 10, 2023 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Mar 22, 2023 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Jun 21, 2022 | Initial | $685,021 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526303
Simple Agreement for Future Equity
Source: Form D, filed Oct 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dustin Freas | Director |
| David Freas | Director |
| Michael Guzman | Executive |
| H. Dean Hart | Executive |
| Justin Molignoni | Director, Executive |
| Curtis Rhine | Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
157 Baltimore Street
Cumberland, MD, 21502
Cumberland, MD, 21502